Speakers
Ania Wronski
Director, Market Development
Mission Bio
Day Two
Thursday November 18, 2021
11:35 am | Singling Out the Cuts: Single-Cell Multi-Modal Analysis for CRISPR- Edited Cells
Max Sellman
Product Manager - Gene Editing
Aldevron
Day One
Wednesday November 17, 2021
11:50 am | CRISPR-Associated Nucleases for Gene Editing: Tools to Support Discovery and Therapeutic Programs
John Murphy
Chief Scientific Officer
Arbor Biotechnologies
Day One
Wednesday November 17, 2021
4:30 pm | Arbor Discovery’s Novel Process and Protein Engineering Approach
Roy Ziblat
Scientific Manager
Arbor Biotechnologies
Day Two
Thursday November 18, 2021
12:45 pm | Function & Discoveries of the Arbor Discovery Line Using Type V Systems
Luisa Loiacono
Senior Research Scientist
AstraZeneca
Day One
Wednesday November 17, 2021
9:00 am | Panel Discussion: Driving CRISPR Technology to the Clinic
Day Two
Thursday November 18, 2021
9:15 am | Safety of CRISPR-Cas9 in Therapy: A Call to Action
Joseph Miano
J. Harold Harrison, MD, Distinguished University Chair in Vascular Biology
Augusta University
Jacob Layer
Senior Scientist, Group Leader
eGenesisbio
Day Two
Thursday November 18, 2021
12:15 pm | Innovating Xenotransplantation with Genome Editing
Pankaj Mandal
Senior Staff Fellow, Office of Tissues & Advanced Therapies, Division of Cellular & Gene Therapies
FDA/CBER
Day One
Wednesday November 17, 2021
8:30 am | FDA’s Regulatory Approach to CRISPR Technology
Kalina Paunovska
Postdoctoral Scholars
Georgia Institute of Technology, Dahlman Lab
Day One
Wednesday November 17, 2021
2:00 pm | CRISPR Delivery via the Use of Lipid Nanoparticles Delivery
Danilo Maddalo
Senior Scientist
Genentech
Day One
Wednesday November 17, 2021
9:00 am | Panel Discussion: Driving CRISPR Technology to the Clinic
Day Two
Thursday November 18, 2021
2:15 pm | SEMMs: Somatically Engineered Mouse Models, A New Tool for Translational Preclinical Research
Danny Dever
Head of Discovery Research
GraphiteBio
Day One
Wednesday November 17, 2021
9:00 am | Panel Discussion: Driving CRISPR Technology to the Clinic
Day Two
Thursday November 18, 2021
3:15 pm | Investigate the Therapeutic Potential of CRISPR Technology in Treating Sickle Cell Disease
Ben Kleinstiver
Assistant Professor
Mass General Hospital & Harvard Medical School
Day One
Wednesday November 17, 2021
4:00 pm | Useful Engineered CRISPR-Cas Enzymes with Enhanced Properties
Sean Burns
Vice President, Disease Biology
Intellia Therapeutics
Day Two
Thursday November 18, 2021
2:45 pm | Development of Systemic CRISPR-based Therapeutics
Gregory Cost
Senior Director of Biology
Metagenomi
Day One
Wednesday November 17, 2021
3:30 pm | Novel CRISPR-Associated Gene-Editing Systems Discovered in Metagenomic Samples Enable Efficient & Specific Genome Engineering For Cell Therapy Development
Brett Staahl
Vice President Platform, Co- Founder
Scribe Therapeutics
Day One
Wednesday November 17, 2021
10:50 am | Solving the Challenges of Editing & In Vivo Delivery
Niren Murthy
Professor, Bioengineering
University of California at Berkeley
Day One
Wednesday November 17, 2021
1:30 pm | New Delivery Vehicles for Gene Editing Enzymes
Andrew Anzalone
Head of Prime Editing Platforms
Prime Medicine
Day Two
Thursday November 18, 2021
10:15 am | Exploring the Potential of Prime Editing
Jyun-Liang “Aaron” Lin
Scientist II
Metagenomi
Day Two
Thursday November 18, 2021
9:45 am | Compact Adenine Base Editor with Novel Microbial Components
Rafi Emmanuel
Senior Vice President, R&D
Emendo Biotherapeutics
Day Two
Thursday November 18, 2021
11:45 am | EMD-101, A Potential Autologous HSC-Based Therapy for ELANE-Related Severe Congenital Neutropenia
Clarence Mills
Research Scientist
Horizon Discovery
Day One
Wednesday November 17, 2021
9:30 am | CRISPR Without the Cut: Introducing Horizon’s CRISPRi Portfolio
Christopher Brown
Director, Discovery
Metagenomi
Day One
Wednesday November 17, 2021
11:20 am | Expanding the Genome Editing Toolbox with Metagenomics
Tomomi Aida
Research Scientist, Feng Lab
Massachusetts Institute of Technology
Channabasavaiah Gurumurthy
Director, Mouse Genome Engineering Core Facility
University of Nebraska Medical Center
Melissa Lokugamage
Venture Capitalist
Alloy Therapeutics
